Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 23, Issue 2, 2001, Pages 93-98

  Dhanikula, A B ^a   Panchagnula, R ^a   Singh, I ^a   Kaur, K J ^a   Kaul, C L ^a   Sekhon, J S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cancer patients; Model independent method; Paclitaxel; PCNONLIN; Pharmacokinetics

Indexed keywords

PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDIAN; MALE; SOLID PHASE EXTRACTION;

EID: 0034953158     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2001.23.2.627937     Document Type: Article

References (14)

1. Non-linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
2. Effect of r-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer
3. Drug therapy: Paclitaxel (taxol)
4. Phase I clinical and pharmacokinetic study of taxol
5. Cytochrome P450 3A-mediated human liver microsomal taxol 6alpha-hydroxylation
6. Pharmaceutical aspects of paclitaxel
7. European - Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High versus low-dose and long versus short infusion
8. Determination of taxoids (paclitaxel and docetaxel) in plasma by high performance liquid chromatography
9. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
10. Effect of plasma protein and tissue binding on the tissue course of drug concentration in plasma
11. Localized paclitaxel delivery
12. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma